title: [Optimizing good use and costs of anticancer drugs: A French inter regional study of the Observatory of Cancer].
abstract: Optimizing the care management of patients is a major issue for our society. In Brittany-Pays-de-la-Loire (almost 10% of French population), an observatory of cancer has been created in 2003. Its main objective was the follow-up of expensive drugs. The knowledge of the use of these drugs in clinical practice has led to development of a thesaurus of good use. Thus, regular exchanges between clinicians have almost totally reduced not medically justified prescriptions by the thesaurus after and before administration to patient. The thesaurus has given away to national guidelines from 2007. For example, in these two regions, optimization of the use of gemcitabine and bevacizumab has allowed to save respectively 2.5 millions euros between 2005 and 2008 and 3 millions euros between 2009 and 2010 (breast cancer only). Optimizing the use of anticancer drugs has allowed a real health economy without any bad impact on patient management. Respecting medical ethics, the main objective remains to optimize health care. This highly participation of clinicians currently allows to reflect together on the relevance of the last chemotherapy.
authors.affiliation: Observatoire dédié au Cancer Bretagne et Pays-de-la-Loire, Siège médical Paul-Papin, 49000 Angers, France. francoise.grude@ico.unicancer.fr
authors.forename: Françoise
authors.initials: F
authors.lastname: Grudé
authors.forename: Réjane
authors.initials: R
authors.lastname: Bessard
authors.forename: Hugues
authors.initials: H
authors.lastname: Bourgeois
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Douillard
authors.forename: Erik
authors.initials: E
authors.lastname: Gamelin
authors.forename: Jean-Philippe
authors.initials: JP
authors.lastname: Metges
authors.forename: Christian
authors.initials: C
authors.lastname: Riché
authors.forename: Anne-Marie
authors.initials: AM
authors.lastname: Vidal
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000191:economics / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000191:economics* / Q000627:therapeutic use*; D000068258:Bevacizumab; D017046:Cost Savings / Q000191:economics; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000191:economics / Q000627:therapeutic use; D016527:Drug Costs; D005602:France; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D058996:Quality Improvement / Q000191:economics* / Q000592:standards; D000093542:Gemcitabine
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D003841:Deoxycytidine; D000068258:Bevacizumab; D000093542:Gemcitabine
keywords: cancer; cost; drugs; good use